Theravance, Inc. (NASDAQ:THRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.

Results 1 - 12 of 12

Recs

0
Member Avatar pchop12316 (75.74) Submitted: 12/17/2014 12:24:31 PM : Outperform Start Price: $14.54 THRX Score: -0.92

just get it

Recs

0
Member Avatar SmartAce (99.87) Submitted: 12/16/2014 12:07:33 PM : Outperform Start Price: $13.09 THRX Score: +10.63

-Lower than Klarman
-Catalyst
-I wish I was a baller

Recs

0
Member Avatar LovinMe (46.08) Submitted: 11/30/2014 7:42:02 PM : Outperform Start Price: $15.10 THRX Score: -1.45

Pharma isn't my favorite but I do like the valuation and dividend on this. Not without it's risks.

Recs

0
Member Avatar manirg (71.51) Submitted: 10/16/2014 11:15:06 AM : Outperform Start Price: $16.60 THRX Score: -19.86

undervalued

Recs

0
Member Avatar asilverp (71.01) Submitted: 8/28/2014 12:45:38 PM : Underperform Start Price: $22.45 THRX Score: +37.17

in the slim event that this company does meet it's growth expectations, it will have a p/e of 285........not exactly cheap.

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 11/13/2013 11:28:03 PM : Outperform Start Price: $26.90 THRX Score: -60.86

It looks like dumping out of my last outperform at 42 was the right move, as the stock has retraced somewhat in the face of large losses as the company enters into the launch phase of their next generation bronchodilators Breo and Anoro. However, I do see more positives on the horizon as initial revenues from Breo and antibiotic Vibativ will be reported in early 2014. The short term catalyst here is the PDUFA for Anoro on December 18, which I expect to be an approval. Theravance is juggling numerous other projects including pipeline respiratory drugs GSK961081 and TD-4208 and phase II psychoactive compound TD-9855. The wild card here is the planned split into separate companies for the respiratory assets and the rest of the pipeline.

Recs

0
Member Avatar withoutlimits (83.15) Submitted: 9/30/2010 7:50:58 PM : Underperform Start Price: $15.48 THRX Score: +84.16

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Recs

0
Member Avatar jsgant13 (99.18) Submitted: 9/13/2010 1:06:44 PM : Outperform Start Price: $11.59 THRX Score: -55.88

Klarman

Recs

0
Member Avatar Brian7992 (67.79) Submitted: 8/20/2009 7:40:30 AM : Outperform Start Price: $12.02 THRX Score: -84.15

Best Bio Bets

Recs

0
Member Avatar jmacn22 (83.30) Submitted: 2/5/2009 12:42:52 PM : Underperform Start Price: $12.48 THRX Score: +129.75

Should underperform

Recs

1
Member Avatar gklein711 (56.26) Submitted: 1/8/2008 1:53:53 PM : Outperform Start Price: $16.48 THRX Score: -61.96

Therevance appears to be a good company, but hit a rough spot. Should rebound from here.

Recs

0
Member Avatar star60629 (77.89) Submitted: 4/30/2007 8:58:01 PM : Underperform Start Price: $25.22 THRX Score: +88.86

Easiest way to find overvalued stocks go thru some biotechs.This one way overpriced Rev 20 Mil shares 60 mil. Insiders selling.Book value $1 . Muahhh look out below.My biotech shorts are outperforming. Get a basket of the worst ones and short.

Results 1 - 12 of 12

Featured Broker Partners


Advertisement